Stock Events

Stock Events

Akari Therapeutics

0

12

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Financials

-Profit Margin

Unprofitable

2020

2021

2022

2023

2024

2025

0Revenue

-15MNet Income

Analyst Ratings

22.76Average Price Target

The highest estimate is 22.76.
From 1 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLAB.MU. It's not an investment recommendation.

Schwab US Dividend Equity

Vanguard S&P 500

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Vertex Pharmaceuticals

Vertex Pharmaceuticals engages in developing treatments for cystic fibrosis and other serious diseases, overlapping with Akari's focus on rare diseases.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals specializes in developing medications for eye diseases, rare diseases, and immune disorders, competing in similar therapeutic areas as Akari.

Biogen focuses on neurology, rare diseases, and autoimmune disorders, areas that overlap with Akari's therapeutic focus.

Amgen develops treatments for serious illnesses in areas like oncology and cardiology, and its work in immune disorders competes with Akari.

Gilead Sciences

Gilead Sciences focuses on antiviral drugs, liver diseases, and inflammatory and respiratory diseases, competing in the broader area of serious and rare diseases.

AbbVie works on chronic autoimmune diseases and more, with its broad focus on serious diseases including areas that compete with Akari's treatments.

Novo Nordisk specializes in diabetes and obesity but is expanding into rare blood disorders, which could compete with Akari's pipeline.

Pfizer has a broad portfolio including treatments for rare diseases and inflammation, making it a competitor in some of Akari's key areas.

Johnson & Johnson

Johnson & Johnson, through its pharmaceutical segment Janssen, develops treatments for a wide range of diseases, including those in competition with Akari's focus areas.

About

Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.

Show more...

CEO

Mr. Abizer Gaslightwala

Employees

6

Country

United Kingdom

ISIN

US00972G1085

Listings

0 Comments

Share your thoughts

FAQ

What is Akari Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Akari Therapeutics stocks are traded under the ticker CLAB.MU.

What is Akari Therapeutics revenue for the last year?▼

Akari Therapeutics revenue for the last year amounts to 0 EUR.

What is Akari Therapeutics net income for the last year?▼

CLAB.MU net income for the last year is -15M EUR.

How many employees does Akari Therapeutics have?▼

As of July 26, 2026, the company has 6 employees.

In which sector is Akari Therapeutics located?▼

Akari Therapeutics operates in the Health & Wellness sector.

When did Akari Therapeutics complete a stock split?▼

The last stock split for Akari Therapeutics was on August 17, 2023 with a ratio of 1:20.

Where is Akari Therapeutics headquartered?▼

Akari Therapeutics is headquartered in Tampa, United Kingdom.